Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):
Stopped: Difficulty recruiting, only one participant in 18 months, rarity of event
United States1 participantsStarted 2012-02
Plain-language summary
This is a double blinded, placebo-controlled trial to determine if IV dexamethasone more quickly than placebo assists resolution of Posterior Reversible Encephalopathy Syndrome (PRES) encountered in eclamptic patients. All patients regardless of assignment to placebo or steroid will receive standard therapy to include magnesium sulfate, blood pressure medications and diuretics. We hypothesize that the addition of dexamethasone to standard therapy will accelerate CNS recovery more quickly than standard management without dexamethasone.
Who can participate
Age range18 Years – 45 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Currently 34 weeks pregnant or within 6 weeks postpartum
✓. At least 18 years of age
✓. Singleton or twin gestation
✓. Patient or family sign informed consent
✓. Diagnosis of eclampsia
✓. Able to obtain MRI scanning within 24hours of hosp admit and/or seizure
Exclusion criteria
✕. Neither pregnant nor within first 6 weeks postpartum
✕. Patient or family unable to sign informed consent
✕. Less than 18 years of age
✕. Triplet or higher order gestation
✕. Unable to obtain MRI scanning within 24 hours of hospital admission (
What they're measuring
1
Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): Arandomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery